NCT07022301View on ClinicalTrials.gov

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2029

Conditions
Small Cell Lung Cancer Extensive StageResistance to Immunotherapy
Interventions
DRUG

sintilimab combined with anlotinib

Patients who met the inclusion criteria were treated with Sintilimab plus anlotinib every 3 weeks until disease progression or intolerable adverse reactions or death(up to 24 months).

All Listed Sponsors
lead

First Affiliated Hospital of Wannan Medical College

OTHER